kabutan

StemRIM(4599) Summary

4599
TSE Growth
StemRIM
301
JPY
+1
(+0.33%)
Apr 28, 3:30 pm JST
1.89
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
3.71
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
300 JPY 1.88 USD
Previous Close Apr 27
300 JPY 1.88 USD
High Apr 28, 9:48 am
304 JPY 1.90 USD
Low Apr 28, 9:15 am
298 JPY 1.87 USD
Volume
76,900
Trading Value
0.02B JPY 0.15M USD
VWAP
301.44 JPY 1.89 USD
Minimum Trading Value
30,100 JPY 189 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
155
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
212
1-Year High May 8, 2025
965
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 2,877,300
Apr 17, 2026 0 2,822,800
Apr 10, 2026 0 2,825,900
Apr 3, 2026 0 2,808,900
Mar 27, 2026 0 2,845,000
Company Profile
StemRIM is a biotech venture originating from Osaka University, developing "regeneration-inducing medicine" that promotes self-tissue regeneration.
Sector
Pharmaceuticals
StemRIM is a research and development-based pharmaceutical venture founded at Osaka University. The company is engaged in the research and development of its proprietary "regeneration-inducing medicine" that promotes self-tissue regeneration and healing. This technology aims to achieve effects equivalent to regenerative medicine without using living cells, instead activating patients' own internal stem cells through compound administration to function broadly against various diseases. The company's lead pipeline product, redasemtide, is currently undergoing clinical trials for epidermolysis bullosa and acute cerebral infarction. Additionally, StemRIM is advancing research and development in a wide range of regeneration-inducing medical technologies, including novel peptides for systemic and local administration, therapeutic autologous cell collection devices, and stem cell gene therapy. Through these technologies, StemRIM aims to overcome the challenges of conventional regenerative medicine and realize safer and more effective treatment methods.